Sanofi's 2022Q1 performance: China increased by 13.4%!

On April 28, Sanofi announced its 2022Q1 results, achieving revenue of 9.

In terms of geographical distribution of revenue, Russia provided Sanofi with the strongest growth driver (+34.

From the perspective of specific varieties, Dupixent is the dominant product and will still be the product that Sanofi relies on most in the short term

Although Sanofi announced on February 19 this year that the Phase III study of Dupixent in the treatment of chronic spontaneous urticaria had failed, this quarter, the product still made a number of important progress, including: 1) It was submitted in the United States and Europe for the treatment of nodular urticaria.

Sales of Kevzara (sarilumab), an IL-6 receptor inhibitor developed in partnership with Regeneron, increased by 61.

The PD-1 monoclonal antibody Libtayo (cemiplimab) and the CD38 monoclonal antibody Sarclisa (isatuximab) in the tumor field are still in the stage of explosive growth, but the base is still small

In addition to the above-mentioned progress on Dupixent, Sanofi has made many progress in the field of rare diseases, new crown vaccines, and anti-tumor:

On February 4, the FDA approved sutimlimab (Enjaymo), the first complement C1s antibody for the treatment of cold agglutinin disease (CAD), to reduce the need for red blood cell transfusions due to hemolysis in patients with CAD

On February 24, jointly with GSK, submitted a marketing application for SARS-CoV-2 adjuvanted recombinant protein vaccine to the European Medicines Agency and the FDA;

and Regeneron announced the voluntary withdrawal of Libtayo (cemiplimab) as a second-line sBLA for advanced cervical cancer

The oral selective estrogen degrader (SERD) amcenestran failed the phase II AMEERA-3 study in patients with locally advanced or metastatic ER+/HER2- breast cancer that progressed before and after hormonal therapy and did not achieve improvement in progression-free survival (PFS) primary endpoint

In the face of the patent cliff crisis, Sanofi is also working hard to supplement its product pipeline through cooperation, transactions and mergers

On February 8, the acquisition of Amunix was completed to expand the T cell engager (TCE) and cytokine therapy pipeline

On March 2, a cooperation agreement was reached with Tianyan Pharmaceutical.

On March 15, reached a strategic cooperation with BlackstoneLife, BlackstoneLife will pay up to 300 million euros to advance the development of Sarclisa subcutaneous formulation;

On March 16, it reached an exclusive cooperation agreement with Seagen, a leader in the ADC field, to design, develop and commercialize antibody-drug conjugates (ADCs) for up to 3 cancer sites

In addition, Sanofi also updated and released the company's new logo on February 3, conveying Sanofi's new visual image and new business focus, representing the company's new starting point

For full-year 2022 results, Sanofi expects low double-digit growth

Attachment: 2022Q1 sales data of main products and table of major events in 2022